selumetinib / docetaxel trihydrate combination therapyselumetinib / dactolisib combination therapyselumetinib / irinotecan combination therapyNon-small cell lung cancerafatinib / selumetinib combination therapyCHIR-265 / selumetinib combination therapyCetuximab / selumetinib combination therapyerlotinib / selumetinib combination therapy
P527
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaResistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group studyThe MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors.Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elementsPhase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244.BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.Selumetinib for the treatment of cancer.A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
P921
Q28371598-565BF6D2-ACE7-4A26-9E3D-CF53EB45EF00Q28423248-6A37B892-250D-478C-9158-7B9AFD7FE155Q28444996-6F5B5706-2808-434C-8BDD-C889A486CDAAQ28445009-E3CD8D04-E607-4026-9F34-E76364B84962Q28445215-0198AC53-6CE9-4822-99A5-4DF343F4FE99Q29920039-1CE94B31-2B76-452E-B7E7-2FA16BE88174Q29938776-6D64BDEE-3D9F-45F9-92B2-E4094E90CD4C
P3354
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Selumetinib
@fr
Selumetinib
@sh
Selumetinib
@sr
selumetinib
@en
type
label
Selumetinib
@fr
Selumetinib
@sh
Selumetinib
@sr
selumetinib
@en
altLabel
ARRY 142886
@en
ARRY-142886
@en
ARRY-886
@en
ARRY142886
@en
AZD 6244
@en
AZD-6244
@en
AZD6244
@en
Koselugo
@en
NSC 741O78
@en
selumetinib
@en
prefLabel
Selumetinib
@fr
Selumetinib
@sh
Selumetinib
@sr
selumetinib
@en
P592
P6366
P638
P661
P662
P665
P683
P1579
P2275
selumetinib
@en
P231
606143-52-6
P232
P233
CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO
P234
1S/C17H15BrClFN4O3/c1-24-8-21- ...... 6-8,22,25H,4-5H2,1H3,(H,23,26)
P235
CYOHGALHFOKKQC-UHFFFAOYSA-N
P2566
100.169.311
P274
C₁₇H₁₅BrClFN₄O₃
P3117
DTXSID3048944
P592
CHEMBL1614701